Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Thyroglobulin Autoantibodies are Associated With Refractoriness to Antithyroid Drug Treatment for Graves’ Disease
source: Internal Medicine
year: 2016
authors: Katahira M, Ogata H
summary/abstract:Objective:
The recurrence rate associated with antithyroid drug (ATD) treatment for Graves’ disease (GD) is high compared with that for radioiodine therapy or surgery. It is important to identify patients in whom remission is unlikely, so that they are not given treatment that is destined to fail. The objective of this study was thus to evaluate factors influencing the prognosis of GD patients treated with ATDs.
Patients:
One hundred and sixty-one patients were divided into two groups: 100 patients who could not discontinue ATDs for eight years or more (refractory group) and 61 patients who achieved remission within eight years after starting ATD treatment (nonrefractory group). The groups were compared in terms of age, thyroid function and thyroid-related autoantibodies at diagnosis, and the durations to the recovery of thyroid function and thyroid-related autoantibodies.
Results:
The baseline levels of free triiodothyronine (T3), free thyroxine (T4), thyroid-stimulating antibodies (TSAbs) and thyroid-stimulating hormone (TSH) receptor antibodies (TRAbs) were high, and the age at diagnosis and the baseline level of thyroglobulin autoantibodies (TgAbs) were low in the refractory group compared with those in the nonrefractory group. The durations to the recovery of TSH, free T4, TRAb and TSAb levels were longer in the refractory group than in the nonrefractory group. No significant difference was observed with regard to thyroid peroxidase autoantibodies.
Conclusion:
We compared the clinical features of these two groups in order to identify factors influencing the prognosis of GD patients treated with ATDs. A low baseline level of TgAbs is associated with the refractoriness of GD to ATD treatment.
DOI: 10.2169/internalmedicine.55.6095
read more
Related Content
-
Radioiodine Therapy Versus Antithyroid Medications for Graves’ DiseaseBackground: Graves' disease is the most...
-
Effects of Treatment Modalities for Graves’ Hyperthyroidism on Graves’ Orbitopathy: A 2015 Italian Society of En...Graves’ disease is the most frequent f...
-
The Second Antithyroid Drug Treatment is Effective in Relapsed Graves’ Disease Patients: A Median 11-Year Foll...Background: Antithyroid drug (ATD) is a...
-
Recurrence of Graves’ Disease is Predicted by Lower Patient Age at Initial Diagnosis: Implications for CareOne of the greatest challenges in managi...
-
A 6-Year Follow-Up of a Randomized Prospective Trial Comparing Methimazole Treatment With or Without Exogenous L-Thy...Objective: Antithyroid drug therapy is ...
-
Effects of Selenium on Short-Term Control of Hyperthyroidism due to Graves’ Disease Treated With Methimazole: ...Objective: In spite of previous conflic...
-
Remission After Potassium Iodide Therapy in Patients With Graves’ Hyperthyroidism Exhibiting Thionamide-Associ...Context: Thionamides have various side ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.